Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?

about

Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?

Item

http://www.wikidata.org/entity/Q52752658

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Immuno-oncology in urothelial ...... mately sit on the iron throne?

@en

Immuno-oncology in urothelial ...... mately sit on the iron throne?

@nl

type

Item

label

Immuno-oncology in urothelial ...... mately sit on the iron throne?

@en

Immuno-oncology in urothelial ...... mately sit on the iron throne?

@nl

prefLabel

Immuno-oncology in urothelial ...... mately sit on the iron throne?

@en

Immuno-oncology in urothelial ...... mately sit on the iron throne?

@nl

P1476

Immuno-oncology in urothelial ...... mately sit on the iron throne?

@en

P2093

Evan Y Yu

http://www.w3.org/2001/XMLSchema#string

Jorge D Ramos

http://www.w3.org/2001/XMLSchema#string

P2860

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

P304

951-954

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2217/IMT-2017-0109

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28971748

http://www.w3.org/2001/XMLSchema#string